Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?

Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transme...

Full description

Bibliographic Details
Main Authors: Behrooz, Amir Barzegar, Amir Hamzah, Amir Syahir
Format: Article
Published: Frontiers Media 2021
Online Access:http://psasir.upm.edu.my/id/eprint/96552/
_version_ 1848862393875038208
author Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
author_facet Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
author_sort Behrooz, Amir Barzegar
building UPM Institutional Repository
collection Online Access
description Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transmembrane glycoprotein, has been used to classify cancer stem cells (CSCs) in GBM. The therapeutic value of CD133 is a biomarker of the CSC in multiple cancers. It also leads to growth and recurrence of the tumor. More recent findings have confirmed the association of telomerase/TERT with Wnt/β-catenin and the PI3K/AKT/mTOR signaling pathways. Advance studies have shown that crosstalk between CD133, Wnt/β-catenin, and telomerase/TERT can facilitate GBM stemness and lead to therapeutic resistance. Mechanistic insight into signaling mechanisms downstream of surface biomarkers has been revolutionized by facilitating targeting of tumor-specific molecular deregulation. This review also addresses the importance of interplay between CD133, Wnt/β-catenin and TERT signaling pathways in GSCs and outlines the future therapeutic goals for glioblastoma treatment.
first_indexed 2025-11-15T13:16:19Z
format Article
id upm-96552
institution Universiti Putra Malaysia
institution_category Local University
last_indexed 2025-11-15T13:16:19Z
publishDate 2021
publisher Frontiers Media
recordtype eprints
repository_type Digital Repository
spelling upm-965522023-01-11T08:45:21Z http://psasir.upm.edu.my/id/eprint/96552/ Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy? Behrooz, Amir Barzegar Amir Hamzah, Amir Syahir Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transmembrane glycoprotein, has been used to classify cancer stem cells (CSCs) in GBM. The therapeutic value of CD133 is a biomarker of the CSC in multiple cancers. It also leads to growth and recurrence of the tumor. More recent findings have confirmed the association of telomerase/TERT with Wnt/β-catenin and the PI3K/AKT/mTOR signaling pathways. Advance studies have shown that crosstalk between CD133, Wnt/β-catenin, and telomerase/TERT can facilitate GBM stemness and lead to therapeutic resistance. Mechanistic insight into signaling mechanisms downstream of surface biomarkers has been revolutionized by facilitating targeting of tumor-specific molecular deregulation. This review also addresses the importance of interplay between CD133, Wnt/β-catenin and TERT signaling pathways in GSCs and outlines the future therapeutic goals for glioblastoma treatment. Frontiers Media 2021 Article PeerReviewed Behrooz, Amir Barzegar and Amir Hamzah, Amir Syahir (2021) Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy? Frontiers in Oncology, 11. art. no. 642719. pp. 1-9. ISSN 2234-943X https://www.frontiersin.org/articles/10.3389/fonc.2021.642719/full 10.3389/fonc.2021.642719
spellingShingle Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_full Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_fullStr Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_full_unstemmed Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_short Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_sort could we address the interplay between cd133, wnt/β-catenin, and tert signaling pathways as a potential target for glioblastoma therapy?
url http://psasir.upm.edu.my/id/eprint/96552/
http://psasir.upm.edu.my/id/eprint/96552/
http://psasir.upm.edu.my/id/eprint/96552/